New drug teduglutide monitored in 250 patients with short bowel syndrome
NCT ID NCT05023382
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study follows 250 people in Japan with short bowel syndrome who are receiving teduglutide (Revestive) injections. Researchers will monitor side effects and how well the drug controls symptoms over 36 months. The goal is to see if teduglutide can safely reduce the need for intravenous nutrition support.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Teduglutide (Revestive) injection
- What this could lead to
- If successful, this could confirm that teduglutide safely reduces the need for intravenous nutrition in people with short bowel syndrome.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. Side effects are possible, and benefits may vary among patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHORT BOWEL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Takeda Selected Site
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Measuring hidden energy needs: a clue to better nutrition for gut failure patients
- Weekly shot could help people with short bowel syndrome absorb more fluids
- New drug could cut IV nutrition needs for short bowel patients
- Could a Plant-Based powder cut the need for IV nutrition?
- Growth hormone shows promise for weaning kids off IV nutrition
- New shot could cut IV feeding for short bowel patients